2min chapter

The HemOnc Pulse cover image

Part One: The Question of MRD in CLL Therapy

The HemOnc Pulse

CHAPTER

Exploring the Selection of BTKIs in Frontline Therapy

Exploring the considerations for selecting BTKIs in frontline therapy, focusing on toxicity profiles, patient comorbidities, and the tolerability of second-generation BTKIs like Daniel and Calibrietinib. Emphasizing patient-specific factors over efficacy differences, this chapter raises unanswered questions in the field.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode